WO2025027577 - MICRORNAS DESIGNED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU FOR THE TREATMENT OF TAUOPATHIES
National phase entry:
Publication Number
WO/2025/027577
Publication Date
06.02.2025
International Application No.
PCT/IB2024/057478
International Filing Date
01.08.2024
Title **
[English]
MICRORNAS DESIGNED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU FOR THE TREATMENT OF TAUOPATHIES
[French]
MICRO-ARN CONÇUS CONTRE LA PROTÉINE TAU ASSOCIÉE AUX MICROTUBULES POUR LE TRAITEMENT DE TAUOPATHIES
Applicants **
CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET)
AVALE, María Elena
Inventors
AVALE, María Elena
Priority Data
63/530,431
02.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2125 | |
| EPO | Filing, Examination, Granting | 9839 | |
| Japan | Filing, Examination, Granting | 2292 | |
| South Korea | Filing, Examination, Granting | 2206 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
22,402
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present description discloses miRNA constructs able to silence tau protein expression. The description also provides methods for treating tauopathies comprising the administration of said miRNA constructs.[French]
La présente invention porte sur des constructions de miARN pouvant inactiver l'expression de la protéine tau. La présente invention concerne également des méthodes de traitement de tauopathies comprenant l'administration desdites constructions de miARN.